4.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency

4.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency

Respiratory Distress Syndrome (RDS), historically referred to as hyaline membrane disease, is the single most common cause of respiratory failure and neonatal intensive care unit (NICU) admission in preterm infants. The fundamental defect is a developmental deficiency in the production and secretion of pulmonary surfactant by alveolar type II pneumocytes. Without adequate surfactant, high alveolar surface tension causes progressive end-expiratory atelectasis, loss of functional residual capacity (FRC), intrapulmonary right-to-left shunting, and life-threatening hypoxemia.

---

1. Surfactant Biochemistry & Biophysics

Biochemical Composition of Pulmonary Surfactant

Pulmonary surfactant is a complex lipoprotein mixture synthesized, packaged into lamellar bodies, and secreted by alveolar type II pneumocytes starting around 24 to 28 weeks of gestation, reaching functional maturity near 35 to 36 weeks. Surfactant consists of approximately 90% lipids and 10% specialized proteins:

1. Phospholipids (~80–85% of total mass):

   • Dipalmitoylphosphatidylcholine (DPPC / Lecithin): Accounts for ~50–60% of all phospholipids. DPPC is the primary surface-tension-lowering molecule. Its two saturated 16-carbon palmitic acid chains pack tightly together at the air-liquid interface, forming an insoluble monolayer capable of reducing surface tension to nearly zero ($< 1-2\text{ mN/m}$) during expiration.
   • Phosphatidylglycerol (PG): Comprises ~8–12% of lipids. PG enhances the rapid lateral spreading of DPPC across the alveolar surface. Its appearance in amniotic fluid at ~35–36 weeks signals biochemical fetal lung maturity.
   • Other Lipids: Phosphatidylethanolamine, phosphatidylinositol (PI), and neutral lipids (cholesterol).

2. Surfactant-Associated Proteins (SP-A, SP-B, SP-C, SP-D):

   • Hydrophobic Proteins (SP-B and SP-C): Essential for biophysical function. SP-B (79 amino acids) and SP-C accelerate the adsorption and insertion of phospholipids into the monolayer film and facilitate tubular myelin lattice formation. Clinical Pearl: Congenital SP-B deficiency (autosomal recessive mutation) causes lethal neonatal respiratory failure in term infants unresponsive to exogenous surfactant.
   • Hydrophilic Collectins (SP-A and SP-D): Function primarily in innate host defense and pulmonary immunity. They bind and opsonize viral, bacterial, and fungal pathogens, regulate alveolar macrophage phagocytosis, and modulate inflammatory cytokine cascades.

The Biophysics of Alveolar Stability: The Law of Laplace

The physical behavior of alveoli is governed by the Law of Laplace for spherical structures:

$P = \frac{2T}{r}$

Where:

• $P$ = Collapsing pressure (inward pressure required to prevent collapse, or opening pressure required to expand the sphere)
• $T$ = Surface tension at the liquid-air interface
• $r$ = Alveolar radius

Without Surfactant (Constant Surface Tension T):
Alveolus A (r = 1) ───► P = 2(10)/1 = 20 cmH2O  [HIGH Pressure ──► Collapses into B]
Alveolus B (r = 2) ───► P = 2(10)/2 = 10 cmH2O  [LOWER Pressure ─► Overdistends]

With Surfactant (Dynamic Surface Tension T drops as r shrinks):
Alveolus A (r = 1, T = 2) ──► P = 2(2)/1 = 4 cmH2O  [STABLE: Pressures equalize]
Alveolus B (r = 2, T = 4) ──► P = 2(4)/2 = 4 cmH2O  [STABLE: No alveolar collapse]

In a surfactant-deficient lung, surface tension ($T$) remains constant and high throughout the respiratory cycle. Consequently, smaller alveoli (smaller $r$) generate significantly higher collapsing pressures ($P$) than larger adjacent alveoli, forcing gas to empty from smaller alveoli into larger ones. This produces diffuse microatelectasis in small units and localized overdistension in larger units. Surfactant dynamically reduces surface tension in direct proportion to alveolar compression: as the alveolus shrinks during expiration, DPPC molecules compress tightly together, driving $T$ close to zero and eliminating the collapsing pressure gradient, thereby preserving alveolar stability and FRC.

---

2. Pathophysiological Cascade of RDS

Surfactant deficiency initiates a self-propagating cycle of mechanical failure, ventilation-perfusion mismatch, tissue injury, and secondary pulmonary hypertension:

1. Loss of Functional Residual Capacity (FRC): Without surfactant, end-expiratory alveolar collapse occurs after every breath. The neonate must exert immense negative intrathoracic pressure (high work of breathing) to reopen collapsed alveoli with each inspiration, leading to diaphragmatic muscle fatigue.
2. Decreased Pulmonary Compliance: The lungs become stiff and non-compliant, requiring high transpulmonary opening pressures.
3. Ventilation-Perfusion ($\dot{V}/\dot{Q}$) Mismatch & Intrapulmonary Shunt: Blood perfuses non-ventilated, collapsed alveoli, creating a massive true right-to-left intrapulmonary shunt that results in severe hypoxemia refractory to simple supplemental oxygen.
4. Hypoventilation & Mixed Acidosis: Progressive atelectasis leads to alveolar hypoventilation, hypercapnia, and respiratory acidosis. Concurrently, severe cellular hypoxia causes anaerobic metabolism, lactic acid accumulation, and metabolic acidosis.
5. Endothelial Damage & Hyaline Membrane Formation: High shear stress from repeated alveolar opening/collapse, combined with ischemic capillary leak, causes protein-rich plasma exudate and fibrin to pour into alveolar spaces. This exudate coagulates into eosinophilic hyaline membranes lining the respiratory bronchioles and alveolar ducts. Fibrin and serum proteins directly inactivate any remaining endogenous surfactant, accelerating lung destruction.

3. Risk Factors & Perinatal Influences

Neonatal RDS risk is strongly modulated by gestational age, maternal metabolic state, mode of delivery, and fetal hormonal milieu.

Key Risk Factors

• Prematurity: The single greatest predictor. Incidence is $> 80-90%$ at $< 28$ weeks, $\sim 50-60%$ at $28-32$ weeks, $\sim 15-20%$ at $32-34$ weeks, and $< 5%$ at $\ge 37$ weeks.
• Maternal Diabetes (Infant of a Diabetic Mother - IDM): Maternal hyperglycemia causes fetal hyperglycemia and compensatory fetal hyperinsulinemia. High fetal insulin levels directly inhibit the transcription of surfactant proteins (SP-A and SP-B) and block cortisol-mediated induction of choline phosphate cytidylyltransferase, delaying biochemical lung maturity by 1 to 2 weeks.
• Cesarean Delivery without Preceding Labor: Labor induces an endogenous surge of fetal catecholamines (epinephrine) and glucocorticoids, which stimulates surfactant exocytosis from lamellar bodies and activates epithelial sodium channels (ENaC) to clear lung liquid. Elective C-section bypasses these hormonal cues.
• Perinatal Asphyxia, Acidosis, and Hypothermia: Alveolar ischemia and cold stress suppress type II pneumocyte metabolism, impairing surfactant synthesis and depleting intracellular ATP stores.
• Male Sex: Androgens delay surfactant production relative to estrogens, conferring a 1.5- to 2-fold higher risk in male preterm infants.
• Multiple Gestations: Second-born twins carry higher risk due to intrapartum hypoxia and cord clamping dynamics.

Protective Perinatal Factors (Accelerated Lung Maturation)

• Antenatal Corticosteroid Therapy: Maternal administration of Betamethasone ($12\text{ mg}$ IM q24h $\times 2$ doses) or Dexamethasone ($6\text{ mg}$ IM q12h $\times 4$ doses) between $24^0$ and $33^6$ weeks (and late preterm $34^0-36^6$ weeks) significantly upregulates surfactant synthesis enzymes, decreases RDS incidence by $\sim 50%$, and reduces intraventricular hemorrhage (IVH) and neonatal mortality.
• Chronic Intrauterine Stress: Maternal preeclampsia, chronic hypertension, placental insufficiency, and prolonged premature rupture of membranes (PPROM) trigger endogenous fetal cortisol release, accelerating structural and biochemical alveolar maturation.

---

4. Clinical Presentation & Physical Assessment

Signs of RDS typically appear immediately in the delivery room or evolve within the first 2 to 4 hours of life, progressively worsening over 48 to 72 hours before natural recovery begins:

1. Tachypnea: Respiratory rate $> 60\text{ breaths/min}$ (often $80-100\text{ bpm}$) as the infant compensates for low tidal volume ($V_t$) by increasing frequency to maintain minute ventilation.
2. Expiratory Grunting: A critical compensatory mechanism. The neonate partially closes the glottis during active expiration against vocal cords, generating positive end-expiratory pressure ($3-5\text{ cmH}_2\text{O}$) to stent open terminal airways and preserve FRC.
3. Nasal Flaring: Reflex dilation of the anterior nares on inspiration, reducing upper airway resistance by up to $30-40%$.
4. Chest Wall Retractions: Intercostal, subcostal, and substernal retractions occur because the preterm infant's highly compliant, cartilaginous ribcage collapses inward when generating high negative intrathoracic pressures against stiff, non-compliant lungs.
5. Paradoxical / Seesaw Respirations: Inward collapse of the anterior chest wall accompanied by outward abdominal distension during inspiration.
6. Central Cyanosis: Dusky or bluish discoloration of mucous membranes, lips, and tongue in room air, reflecting severe arterial hypoxemia.
7. Auscultation: Bilateral diminished breath sounds with a harsh, tubular quality, accompanied by fine end-inspiratory crackles.

The Silverman-Anderson Retraction Score

The Silverman-Anderson score provides a standardized 0-to-10 metric for serial quantification of neonatal respiratory distress (higher score = more severe distress):

Interpretation: Score 0 = No respiratory distress; Score 1–3 = Mild distress; Score 4–6 = Moderate distress; Score 7–10 = Severe distress / impending respiratory failure.

---

5. Diagnostic Evaluation: Imaging & Blood Gases

Chest Radiography (CXR)

• Classic Triad:
  1. Diffuse Reticulogranular Pattern: Uniform, bilateral, finely mottled "ground-glass" parenchymal appearance resulting from widespread microatelectatic alveolar clusters interspersed with aerated alveolar ducts.
  2. Prominent Air Bronchograms: Dark, air-filled major tracheobronchial branches visualized in sharp relief against the surrounding dense, opacified, collapsed lung parenchyma.
  3. Hypoaeration / Underinflation: Diminished lung volumes with $< 8$ posterior ribs visible above the diaphragm on inspiration (bell-shaped thorax).
• Radiographic Staging: Stage I (fine mild granularity) $\rightarrow$ Stage II (moderate granularity with air bronchograms) $\rightarrow$ Stage III (dense confluent opacities with blurred cardiac and diaphragmatic borders) $\rightarrow$ Stage IV (complete "white-out" with total absence of air aeration).

Arterial Blood Gas (ABG) Characteristics

• Early Phase: Hypoxemia ($\text{PaO}_2 < 50\text{ mmHg}$ on room air) with normal or mildly elevated $\text{PaCO}_2$ ($45-50\text{ mmHg}$).
• Progressive Phase: Severe respiratory acidosis ($\text{pH} < 7.25$, $\text{PaCO}_2 > 55-70\text{ mmHg}$) and secondary lactic metabolic acidosis ($\text{HCO}_3^- < 18\text{ mEq/L}$, Base Deficit $> -6\text{ mEq/L}$). In severe cases, intrapulmonary and intracardiac right-to-left shunts cause refractory hypoxemia.

---

6. Comprehensive Clinical Management & Nursing Priorities

1. Non-Invasive Respiratory Support (First-Line)

• Early CPAP: Initiating Continuous Positive Airway Pressure ($5-7\text{ cmH}_2\text{O}$) via binasal prongs or nasal mask immediately in the delivery room or nursery recruits collapsed alveoli, establishes FRC, prevents alveolar collapse at end-expiration, and reduces the need for endotracheal intubation and mechanical ventilation.
• Heated Humidified High-Flow Nasal Cannula (HFNC): Flows of $4-8\text{ L/min}$ provide dead-space washout and mild positive distending pressure in stable recovering infants.

2. Exogenous Surfactant Replacement Therapy

Surfactant is indicated when clinical RDS diagnosis is established and the infant fails non-invasive CPAP (typically defined as requiring $\text{FiO}_2 > 0.30$ on $\text{CPAP} \ge 6\text{ cmH}_2\text{O}$ or exhibiting severe retractions/acidosis).

Administration Modalities

• LISA / MIST (Less Invasive Surfactant Administration / Minimally Invasive Surfactant Therapy): While the infant breathes spontaneously on non-invasive CPAP, a thin vascular catheter (16–18G) or feeding tube is placed through the vocal cords via direct laryngoscopy or video laryngoscopy. Surfactant is slowly instilled over 1 to 3 minutes. This avoids positive pressure bag ventilation and endotracheal intubation, preserving natural spontaneous breathing mechanics.
• INSURE Method: INtubate $\rightarrow$ SURfactant administration via endotracheal tube $\rightarrow$ rapid Extubation to CPAP within 10 to 60 minutes.

Critical Post-Surfactant Nursing Priorities & Safety Warnings

• Rapid Compliance Surge: Exogenous surfactant dramatically increases alveolar compliance within minutes of instillation. If ventilator settings are not rapidly adjusted, the delivered tidal volumes and transpulmonary pressures will skyrocket.
• Immediate Weaning Mandate: The nurse and team must immediately wean Peak Inspiratory Pressure (PIP), Tidal Volume ($V_t$), and $\text{FiO}_2$ to prevent alveolar rupture, pulmonary air leaks (pneumothorax, pulmonary interstitial emphysema [PIE]), and acute hyperoxia.
• Hyperoxia & ROP Prevention: Excessive arterial oxygen tension ($\text{PaO}_2 > 80-100\text{ mmHg}$) damages immature retinal vasculature, causing vasoconstriction, endothelial necrosis, and subsequent Retinopathy of Prematurity (ROP), as well as pulmonary oxygen toxicity (Bronchopulmonary Dysplasia [BPD]). Target pulse oximetry must be strictly maintained within safe ranges (preterm: $90-95%$).